Tesaro, Inc. - Product Pipeline Review - 2015

Published: Mar, 2015 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tesaro, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Tesaro, Inc. - Product Pipeline Review - 2015', provides an overview of the Tesaro, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tesaro, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Tesaro, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tesaro, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Tesaro, Inc.'s pipeline products

Reasons To Buy

- Evaluate Tesaro, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tesaro, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tesaro, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tesaro, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tesaro, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Tesaro, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Tesaro, Inc. Snapshot 5
Tesaro, Inc. Overview 5
Key Information 5
Key Facts 5
Tesaro, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Tesaro, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Tesaro, Inc. - Pipeline Products Glance 10
Tesaro, Inc. - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
Tesaro, Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Tesaro, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Tesaro, Inc. - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Tesaro, Inc. - Drug Profiles 16
rolapitant hydrochloride 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
niraparib 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
TSR-011 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody to Inhibit LAG-3 for Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody to Inhibit TIM-3 for Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
TSR-042 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody to Inhibit PD-1 and TIM-3 for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Tesaro, Inc. - Pipeline Analysis 26
Tesaro, Inc. - Pipeline Products by Target 26
Tesaro, Inc. - Pipeline Products by Route of Administration 28
Tesaro, Inc. - Pipeline Products by Molecule Type 29
Tesaro, Inc. - Pipeline Products by Mechanism of Action 30
Tesaro, Inc. - Recent Pipeline Updates 31
Tesaro, Inc. - Dormant Projects 37
Tesaro, Inc. - Company Statement 38
Tesaro, Inc. - Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Tesaro, Inc., Key Information 5
Tesaro, Inc., Key Facts 5
Tesaro, Inc. - Pipeline by Indication, 2015 7
Tesaro, Inc. - Pipeline by Stage of Development, 2015 8
Tesaro, Inc. - Monotherapy Products in Pipeline, 2015 9
Tesaro, Inc. - Pre-Registration, 2015 10
Tesaro, Inc. - Phase III, 2015 11
Tesaro, Inc. - Phase I, 2015 12
Tesaro, Inc. - Preclinical, 2015 13
Tesaro, Inc. - Discovery, 2015 14
Tesaro, Inc. - Unknown, 2015 15
Tesaro, Inc. - Pipeline by Target, 2015 27
Tesaro, Inc. - Pipeline by Route of Administration, 2015 28
Tesaro, Inc. - Pipeline by Molecule Type, 2015 29
Tesaro, Inc. - Pipeline Products by Mechanism of Action, 2015 30
Tesaro, Inc. - Recent Pipeline Updates, 2015 31
Tesaro, Inc. - Dormant Developmental Projects,2015 37